Measuring the Impact of Taking Care in the Context of an Innovative System for Keeping Dependent Elderly People in Their Homes (DIAPASON)

January 11, 2023 updated by: Gérond'if
The purpose of this study is to compare life quality of patients taking care by DIAPASON 92 with patients or residents from control group EHPAD (retirement home)

Study Overview

Detailed Description

This study has two components: a quantitative component(for users and caregivers) and a qualitative component (for users, caregivers and professionals)

About population :

For quantitative component: the investigators have two arms:

  • Diapason 92 arm: will be constitued by older patients with loss of autonomy, living at home and benefiting from Diapason 92 device
  • Control arm: will be constituted by people residing at the EHPAD (retirement home)

For qualitative component: Study will cover 5 different populations since it concerns both:- - Diapason 92 professionals who work directly with users

  • Daipason 92 Supervisory staff
  • Diapason 92 professional partners, including referring physicians.
  • The users
  • Non-professional helpers of users

Conduct of study:

- About quantitative component:

After verification of eligibility criteria adapted to each centre and once the non-opposition has been collected and subjects have been included, the following data will be collected at M0, M3, M6 and M12:

  • For patients : Start date of care by Diapason 92 or EHPAD, Quality of Life score, benefit evaluation, Socio-educational level, evaluation of disruptive behaviour disorders, economic indicators, somatic comorbidities, collection of psychiatric follow-up if available, independence, nutritional status, factors(s) that motivated care, cognitive assessment, balance assessment, depression screening, ergonomic assessment (only for Diapason 92
  • Family caregiver: 3 measures will be collected: Measuring the burden by Zarit scale, self-assessment of his quality of life and psychological condition
  • About quality component:

A socio-demographic heel will be collected for each participant interviewed who has given no objection to participating in the study. His agreement on the recording of his voice will also collected.

For all participants, following data will be collected: Age, sex, occupation, date and duration of the interview, relationship with the Diapason 92 user (for family caregivers) and the recovery of socio-demographic data of the case report form (for users)

Study Type

Observational

Enrollment (Anticipated)

86

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Ile-de-France
      • Paris, Ile-de-France, France, 75013
        • Recruiting
        • Geriatric department , Broca Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

For quantitative component: we have two arms:

  • Diapason 92 arm: will be constitued by older patients with loss of autonomy, living at home and benefiting from Diapason 92 device
  • Control arm: will be constituted by people residing at the EHPAD (retirement home)

For qualitative component: Study will cover 5 different populations since it concerns both:

  • Diapason 92 professionals who work directly with users
  • Daipason 92 Supervisory staff
  • Diapason 92 professional partners, including referring physicians.
  • The users
  • Non-professional helpers of users

Description

Patient/Resident Inclusion Criteria

  • Age ≥ 60 years old.
  • (Group iso-resources) GIR ≤ 4
  • Beneficiary of treatment by Diapason 92 or resident at EHPAD Aulagnier for more than 6 months.
  • Not exhibiting severe disruptive behaviour disorders (on NPI-ES all FXG 12 and resonance 4 scores).
  • Affiliate or entitled to a sickness insurance scheme
  • Patient or legal representative expressed no objection

Patient/Resident Exclusion Criteria:

  • Age < 60 years old
  • GIR ˃ 4
  • Not affiliated or entitled to a sickness insurance scheme
  • Patient or legal representative did not express no objection

Professionals and caregivers Inclusion Criteria:

  • Exercise within Diapason 92 device or be identified as assisting a Diapason 92 user or be a professional partner of Diapason 92 device
  • Have expressed no objection to participating in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Other

Cohorts and Interventions

Group / Cohort
DIAPASON 92 arm
Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
Control arm
Arm will be constituted by people residing at the EHPAD (retirement home)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of life quality according Nottingham Health Profile (NHP) scale
Time Frame: 12 months
Difference in 12-month quality of life scores (Nottingham Health Profile) between the 2 groups (Diapason 92 and EHPAD).
12 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Assessment of the level of loss of autonomy of an elderly people according Autonomy, gerontology Iso Resources Group (AGGIR) scale
Time Frame: 12 months
12 months
Assessment of functional status according Lawton Instrumental Activities of Daily Living (IADL) Scale
Time Frame: 12 months
12 months
Assessment of activities of daily living, self-care, and independence according Activities of Daily Living (ADL) Scale
Time Frame: 12 months
12 months
Assessment of comorbidity according Charlson scale
Time Frame: 12 months
12 months
Assessment of cognitive function according Mini-Mental State Examination (MMSE) scale
Time Frame: 12 months
12 months
Assessment of disorders of disruptive behaviour according (NPI-ES) scale
Time Frame: 12 months
12 months
Assessment of geriatric depression according Geriatric Depression Scale (GDS) scale
Time Frame: 12 months
12 months
Measuring of burden of the close caregivers according Popular Caregiver Self-report measure Burden (ZARIT)
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Olivier Phd Hanon, Geriatric department, Broca hospital (Paris)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 29, 2019

Primary Completion (Anticipated)

December 31, 2023

Study Completion (Anticipated)

April 26, 2024

Study Registration Dates

First Submitted

June 4, 2019

First Submitted That Met QC Criteria

June 5, 2019

First Posted (Actual)

June 6, 2019

Study Record Updates

Last Update Posted (Actual)

January 12, 2023

Last Update Submitted That Met QC Criteria

January 11, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe